December 16, 2020
1 min watch
Save
Recent RCC research highlights benefits of combination immunotherapy
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
In this video, Elizabeth Plimack, MD, chief of the division of genitourinary medical oncology at Fox Chase Cancer Center, discussed the most exciting developments in renal cell carcinoma in the past year.
New data from large, randomized trials of combination immunotherapy with VEGF inhibition, for instance, have yielded positive results while longer-term follow-up from older studies are also encouraging, she said.
Click here to watch the next video in the series on important issues in diagnosis and treatment of RCC.
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interview
Disclosures:
Plimack reports serving as a scientific advisor for Bristol-Myers Squibb, Genentech, MEI, Merck and Seattle Genetics; conducting data safety monitoring for AstraZeneca, Pfizer and Infinity Pharma; receiving honorarium for CME presentations from ASCO GU, Clinical Care Options, Fox Chase Cancer Center, Mt. Sinai Icahn School of Medicine, NCCN, The Ohio State University, OncLive, PER, Research to Practice, Spire Learning and University of Hawaii; and receiving grants for clinical research from Astellas, Bristol-Myers Squibb, Genentech and Merck.
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.